Re: COVID-19 vaccine associated cervical lymphadenopathy: correspondence.

Dear Editor,

We would like to correspond on the publication ‘COVID‐19 vaccine associated cervical lymphadenopathy: a case series’. With increasing levels of COVID‐19 immunization and booster vaccinations, Heaven et al. predicted that cases of COVID‐19 vaccine‐associated cervical lymphadenopathy would continue to emerge. The necessity of obtaining a COVID‐19 immunization history and adding COVID‐19 linked cervical lymphadenopathy in the differential diagnosis of a neck lump was noted by Heaven et al.

We agree that people who received the vaccine could suffer unanticipated cervical lymphadenopathy. It is frequently tough to tell the difference between a vaccine‐induced condition and other diseases. Lane et al. suggested that the prolonged time for resolution of axillary lymphadenopathy after vaccination supports not delaying screening mammography due to recent COVID‐19 vaccination, as well as the recent professional society recommendation of a follow‐up interval of at least 12 weeks for suspected vaccine‐related lymphadenopathy. A similar approach could be used in cases of cervical lymphadenopathy following immunization. The purpose of the test could be to rule out cancer. However, in an endemic area, it is also vital to rule out other infectious diseases such as tuberculosis.

Author contributions

Pathum Sookaromdee: Conceptualization; validation; visualization; writing – original draft. Viroj Wiwanitkit: Conceptualization; supervision; validation; visualization.